Health Catalyst (NASDAQ:HCAT) Director Julie Larson-Green Sells 47,997 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Julie Larson-Green sold 47,997 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $2.67, for a total transaction of $128,151.99. Following the sale, the director directly owned 73,573 shares of the company’s stock, valued at approximately $196,439.91. This represents a 39.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Health Catalyst Stock Performance

Shares of NASDAQ HCAT opened at $2.61 on Wednesday. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.46. The firm’s 50-day moving average price is $2.83 and its two-hundred day moving average price is $3.29. Health Catalyst, Inc. has a 52-week low of $2.02 and a 52-week high of $8.52. The stock has a market capitalization of $184.61 million, a P/E ratio of -1.64 and a beta of 1.72.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Monday, November 10th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.05 by $0.01. The company had revenue of $76.32 million during the quarter, compared to analyst estimates of $75.05 million. Health Catalyst had a negative return on equity of 6.67% and a negative net margin of 34.05%. As a group, sell-side analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Analyst Ratings Changes

HCAT has been the topic of a number of recent research reports. Canaccord Genuity Group cut their target price on Health Catalyst from $9.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, August 29th. William Blair reaffirmed an “outperform” rating on shares of Health Catalyst in a report on Tuesday, November 11th. Citigroup reduced their target price on shares of Health Catalyst from $3.50 to $3.25 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Stifel Nicolaus decreased their target price on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating for the company in a research report on Tuesday, November 11th. Finally, Piper Sandler lowered shares of Health Catalyst from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $8.00 to $4.00 in a research note on Wednesday, August 27th. Five analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Health Catalyst presently has a consensus rating of “Hold” and an average price target of $4.36.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new stake in shares of Health Catalyst during the 1st quarter worth about $54,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Health Catalyst by 172.6% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 694,361 shares of the company’s stock valued at $3,145,000 after acquiring an additional 439,599 shares in the last quarter. Invesco Ltd. increased its stake in shares of Health Catalyst by 22.2% during the first quarter. Invesco Ltd. now owns 97,599 shares of the company’s stock valued at $442,000 after acquiring an additional 17,725 shares during the period. Nuveen LLC bought a new stake in Health Catalyst during the first quarter worth approximately $2,674,000. Finally, Algert Global LLC acquired a new stake in Health Catalyst in the first quarter worth approximately $141,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.